[New painkillers inhibiting the physiological breakdown of endogenous opioids].
Bernard P
BP
Roques
Marie-Claude
MC
Fournié-Zaluski
Michel
M
Wurm
D000698:Analgesia / Q000379:methods / Q000639:trends; D000700:Analgesics / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D004220:Disulfides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015536:Down-Regulation / Q000187:drug effects; D015195:Drug Design; D015507:Drugs, Investigational / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008954:Models, Biological; D018847:Opioid Peptides / Q000378:metabolism*; D011437:Propylamines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D059748:Proteolysis / Q000187:drug effects*
C534222:1-(2-((1-ethoxycarbonyloxyethoxycarbonylmethyl)carbamoyl)-3-phenylpropyldisulfanylmethyl)-3-methylsulfanylpropylamine; D000700:Analgesics; D004220:Disulfides; D015507:Drugs, Investigational; D018847:Opioid Peptides; D011437:Propylamines